TNFSF10 and neoplasm: This poor preclinical anti-tumor activity of Apo2L/TRAIL could, at least in part, be attributed to its limited clustering ability, possibly restricting it to forming only trimers of DR5 (Fig. 1a), and/or to its short circulation life (minutes), which limits exposure to the tumor.